#VisualAbstract: Neoadjuvant paclitaxel, trastuzumab, and pertuzumab regimen shows high cost-effectiveness for ERBB2-positive breast cancer

byTeddy Guo

December 23, 2020

in StudyGraphics

Reading Time: 1 min read

Special Report: Vaccines in Development Part 3: Oxford/AstraZeneca vaccine showing promise

RelatedReports

Lessons from real-world implementation of lung cancer screening

Chronic Disease

Trastuzumab deruxtecan showed therapeutic efficacy in HER2-mutant non-small cell lung cancer

January 20, 2022

#VisualAbstract: Hereditary retinoblastoma survivors are at an increased risk for melanoma and non-melanoma skin cancers

StudyGraphics

#VisualAbstract: Taxane monotherapy may be more effective for patients with recurrent or metastatic head and neck cancer and prior nivolumab exposure

January 5, 2022

StudyGraphics

#VisualAbstract: Positron emission tomography effective at assessing early tumor response to induction chemotherapy in esophageal or esophagogastric junction cancers

December 12, 2021

Genetic, environmental risk assessment does not increase colon cancer screening

Chronic Disease

Capecitabine + oxaliplatin chemoradiotherapy does not increase survival, but increases toxicity, compared to capecitabine alone in the postoperative treatment of rectal cancer

December 3, 2021

Severe subtype of acute lymphoblastic leukemia susceptible to FDA-approved kinase inhibitors

Allogeneic anti-CD19 T cell therapy shows a manageable safety profile in pediatric and adult patients with high risk B-cell acute lymphoblastic leukemia

Mutation linked with decrease in cutaneous diffuse large B-cell lymphoma

Patients with hematological malignancies and concomitant COVID-19 have worse health outcomes

#VisualAbstract: Adjunctive methylprednisolone treatment for hepatitis B acute-on-chronic liver failure associated with increased survival

#VisualAbstract: Enteral water-soluble vitamin A in extremely preterm infants does not reduce severity of bronchopulmonary dysplasia

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

#VisualAbstract: Neoadjuvant paclitaxel, trastuzumab, and pertuzumab regimen shows high cost-effectiveness for ERBB2-positive breast cancer

Trastuzumab deruxtecan showed therapeutic efficacy in HER2-mutant non-small cell lung cancer

#VisualAbstract: Taxane monotherapy may be more effective for patients with recurrent or metastatic head and neck cancer and prior nivolumab exposure

#VisualAbstract: Positron emission tomography effective at assessing early tumor response to induction chemotherapy in esophageal or esophagogastric junction cancers

Special Report: Vaccines in Development Part 3: Oxford/AstraZeneca vaccine showing promise

Allogeneic anti-CD19 T cell therapy shows a manageable safety profile in pediatric and adult patients with high risk B-cell acute lymphoblastic leukemia

RelatedReports

Trastuzumab deruxtecan showed therapeutic efficacy in HER2-mutant non-small cell lung cancer

#VisualAbstract: Taxane monotherapy may be more effective for patients with recurrent or metastatic head and neck cancer and prior nivolumab exposure

#VisualAbstract: Positron emission tomography effective at assessing early tumor response to induction chemotherapy in esophageal or esophagogastric junction cancers

Capecitabine + oxaliplatin chemoradiotherapy does not increase survival, but increases toxicity, compared to capecitabine alone in the postoperative treatment of rectal cancer

Allogeneic anti-CD19 T cell therapy shows a manageable safety profile in pediatric and adult patients with high risk B-cell acute lymphoblastic leukemia

Patients with hematological malignancies and concomitant COVID-19 have worse health outcomes

#VisualAbstract: Enteral water-soluble vitamin A in extremely preterm infants does not reduce severity of bronchopulmonary dysplasia

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

Get Full Access

Recent Reports

Welcome Back!

Create New Account!

Retrieve your password

#VisualAbstract: Neoadjuvant paclitaxel, trastuzumab, and pertuzumab regimen shows high cost-effectiveness for ERBB2-positive breast cancer

RELATED REPORTS

Special Report: Vaccines in Development Part 3: Oxford/AstraZeneca vaccine showing promise

Allogeneic anti-CD19 T cell therapy shows a manageable safety profile in pediatric and adult patients with high risk B-cell acute lymphoblastic leukemia

RelatedReports

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

Get Full Access

Recent Reports

Welcome Back!

Create New Account!

Retrieve your password